It has already been shown that Skp2 deficiency can enhance sensitivity of leukemia cells to chemotherapy [62] and Skp2 is itself being increasingly considered a possible target for breast cancer and prostate cancer therapy [63], [64]. The gene discussed is SKP2; the disease is Familial prostate cancer.